Moot S K, Peters G N, Cheek J H
Cancer. 1987 Aug 1;60(3):382-5. doi: 10.1002/1097-0142(19870801)60:3<382::aid-cncr2820600316>3.0.co;2-j.
To ascertain the prognostic significance of tumor hormone receptor status in node negative, premenopausal patients with breast cancer, a retrospective view of 199 patients fitting these criteria was conducted. Of these 199 patients, 147 had estrogen receptor data available. There were 104 patients (71%) who were estrogen receptor negative, and 16 (15%) had developed local or distant recurrence with a median follow-up of 44 months. Five patients had died of breast cancer. Of the 43 patients who were estrogen receptor positive, there was one recurrence, and no breast cancer deaths. This difference in recurrence is statistically significant (P less than 0.01) by the log-rank probability test. Of the 17 patients with recurrent disease, 14 (82%) had primary tumors 2 cm or larger in size. If only those patients with tumors 2 cm or larger are considered, 23% (13/57) who were estrogen receptor negative and 5% (1/19) who were estrogen receptor positive recurred. This remains statistically significant (P less than 0.025). We conclude that tumor hormone receptor status and size of tumor are significant prognostic factors in identifying premenopausal, node negative women at risk for recurrent disease.
为确定肿瘤激素受体状态在淋巴结阴性的绝经前乳腺癌患者中的预后意义，我们对符合这些标准的199例患者进行了回顾性研究。在这199例患者中，147例有雌激素受体数据。104例患者（71%）雌激素受体阴性，其中16例（15%）出现局部或远处复发，中位随访时间为44个月。5例患者死于乳腺癌。43例雌激素受体阳性的患者中，有1例复发，无乳腺癌死亡病例。通过对数秩概率检验，复发率的这种差异具有统计学意义（P<0.01）。在17例复发患者中，14例（82%）原发肿瘤大小为2 cm或更大。如果仅考虑肿瘤大小为2 cm或更大的患者，雌激素受体阴性患者的复发率为23%（13/57），雌激素受体阳性患者的复发率为5%（1/19）。这仍具有统计学意义（P<0.025）。我们得出结论，肿瘤激素受体状态和肿瘤大小是识别有疾病复发风险的绝经前、淋巴结阴性女性的重要预后因素。
